| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8409767 | Drug Discovery Today | 2018 | 20 Pages |
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a keratinocyte-derived skin tumor. It is the second-most-common cancer affecting the Caucasian population and is responsible for >20% of all skin-cancer-related deaths. The estimated incidence of non-melanoma skin cancer in the USA is >1Â 000Â 000 cases per year, of which roughly 20-30% are squamous cell carcinoma. To better understand and treat this challenging cancer, current research focuses on development of novel strategies to improve the understanding of tumor biogenesis on an individual basis. microRNAs are becoming important biomarkers in the diagnosis, prognosis and treatment of cSCC. This review describes the current knowledge on miRNA expression in cSCC and its role as a biomarker for personalized medicine.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Kathryn Konicke, Argelia López-Luna, José Luis Muñoz-Carrillo, Luis Steven ServÃn-González, Armando Flores-de la Torre, Edit Olasz, Zelmira Lazarova,